Correlation between centromere protein-F autoantibodies and cancer analyzed by enzyme-linked immunosorbent assay

Simon Welner1,2, Nicole Hartwig Trier1,3, Morten Frisch4, Henning Locht1,5, Paul Robert Hansen3 and Gunnar Houen1*

Abstract

Background: Centromere protein-F (CENP-F) is a large nuclear protein of 367 kDa, which is involved in multiple mitosis-related events such as proper assembly of the kinetochores, stabilization of heterochromatin, chromosome alignment and mitotic checkpoint signaling. Several studies have shown a correlation between CENP-F and cancer, e.g. the expression of CENP-F has been described to be upregulated in cancer cells. Furthermore, several studies have described a significant correlation between the expression of autoantibodies to CENP-F and cancer.

Methods: Autoantibodies to CENP-F were detected in a small number of samples during routine indirect immunofluorescence (IIF) analysis for anti-nuclear antibodies (ANA) using HEp-2 cells as substrate. Using overlapping synthetic peptides covering a predicted structural maintenance of chromosomes (SMC) domain, we developed an enzyme-linked immunosorbent assay (ELISA) for detection of CENP-F antibodies.

Results: Analyzing the reactivity of the sera positive in IIF for CENP-F antibodies to overlapping CENP-F peptides, we showed that autoantibodies to several peptides correlate with the presence of antibodies to CENP-F and a diagnosis of cancer, as increased CENP-F antibody expression specific for malignant cancer patients to five peptides was found (A9, A12, A14, A16, A27). These antibodies to CENP-F in clinical samples submitted for ANA analysis were found to have a positive predictive value for cancer of 50%. Furthermore, the expression of cancer-correlated CENP-F antibodies seemed to increase as a function of time from diagnosis.

Conclusion: These results conform to previous findings that approximately 50% of those patients clinically tested for ANA analyses who express CENP-F antibodies are diagnosed with cancer, confirming that these antibodies may function as circulating tumor markers. Thus, a peptide-based CENP-F ELISA focused on the SMC domain may aid in identifying individuals with a potential cancer.

Keywords: Centromere protein-F, Autoantibodies, Immunofluorescence, ELISA, Cancer

Background

Cancer occurs in many forms and the prognosis varies from good to extremely bad. For most forms of cancer, the prognosis is better, the earlier a diagnosis is established [1,2]. Consequently, screening for biomarkers is used to reveal early stages of disease or precancerous conditions. Such tumor markers can be substances released by cancer cells, circulating tumor cells or markers of an immune response against tumor components [2-6]. In general, immune responses against tumor cells are weak or non-detectable. However, in some cases characteristic autoantibodies are found in high titers in serum and have diagnostic value, e.g. paraneoplastic antibodies associated with paraneoplastic neurologic syndromes, which are believed to result from an autoimmune attack on neuronal tissue, spurred by similar neuronal antigens ectopically expressed in tumor cells [7,8].

Other examples of autoantibodies related to cancer include autoantibodies directed to centromere protein-F...
(CENP-F), also referred to as mitosin. These antibodies were originally suggested to be potential tumor markers by Casiano et al. [9]. They evaluated the clinical histories of 26 patients, who were found to express antibodies to CENP-F by indirect immunofluorescence (IIF). Of these 26 patients, 14 (54%) had various cancer types, while six (23%) had other disorders related to increased or abnormal cell proliferation, indicating a possible correlation between CENP-F antibodies and cancer. These findings were supported by Rattner et al. [10]. Analyzing CENP-F antibody expression in 36 sera from anti-CENP-F-positive patients, including the 26 patients originally examined by Casiano et al. [9], they reported that 22 of the 36 patients (61%) had neoplasms. Based on antibody screening, applying three larger fragments of the CENP-F protein, they concluded that the correlation between cancer diagnosis and CENP-F antibodies was more significant, the closer to the C-terminal end the autoantibodies showed reactivity. While the studies by Casiano et al. [9] and Rattner et al. [10] mainly described a correlation with breast and lung cancer, similar correlations have been described for other cancer types. For example, Bencimon et al. [11] detected a significant correlation between CENP-F antibody expression and non-Hodgkin’s lymphoma (NHL) by screening 347 NHL patients along with 150 controls using a radioimmunoassay (RIA) and IIF. According to their findings, a significantly higher prevalence of CENP-F antibodies was detected in sera from NHL patients (7.2%) compared to controls (1.3%) by RIA (P < 0.01). In comparison, a prevalence of only 2.9% in sera from NHL patients compared with none of the sera from control patients was found when employing IIF, demonstrating a better sensitivity of the RIA technique. Similarly, a correlation between chronic graft versus host disease and the expression of antibodies to CENP-F has been described [12].

CENP-F is a 367 kDa protein of 3210 amino acids, which is involved in centromere formation and kinetochore organization during mitosis [13-16]. The protein is predicted to contain several structural features and motifs including coiled-coil, tandem repeats, leucine zippers and structural maintenance of chromosomes (SMC) domains [17-19]. Moreover, CENP-F has been experimentally shown to have several domains with distinct functions, including interaction with chromatin [19], retinoblastoma protein [13] and transcription factor ATF4 [20]. CENP-F contains a nuclear localization sequence [21], and it can be post-translationally modified by phosphorylation [13,21], acetylation [22] and farnesylation [23] (Figure 1).

Only limited information on the antigenic regions of CENP-F has been obtained. Studies by Rattner et al. [10] indicate that the C-terminal end is especially antigenic, however the exact regions remain to be determined. Recently, we characterized the reactivity of two independent monoclonal antibodies to CENP-F directed to regions of the predicted SMC prok A domain (amino acids 1882-2153), and showed that they recognize a linear epitope (NELSRIRSEKA, residues 1998-2008) in a putative coiled-coil region [24], confirming the antigenicity of this region.

In this study, we examined the reactivity of autoantibodies to CENP-F in patient sera to CENP-F peptides, found by routine IIF screening to exhibit the characteristic nuclear speckled-II (NSp-II) fluorescence pattern [25], which is characteristic for CENP-F antibodies. We focused on the predicted SMC prok A domain and designed overlapping 20-mer peptides, which were screened by ELISA for reaction with anti-CENP-F-
positive patient sera. The results confirmed previous findings by Casiano et al. [9] and Rattner et al. [10], suggesting that approximately 50% of the NSp-II-positive sera had a cancer diagnosis. Moreover, antibody reactivity to specific CENP-F peptides could be correlated with this diagnosis.

**Results**

**ANA results and diagnoses**

Out of 175,000 samples submitted for routine ANA screening, 42 revealed the characteristic NSp-II CENP-F pattern in IIF. These 42 samples were from 28 different individuals that were listed in groups according to their diagnoses (Table 1): invasive cancer (14 individuals, 50%), benign tumor (five individuals, 18%), and no registered neoplasias (nine individuals, 32%), mainly representing various connective tissue diseases. A representative NSp-II fluorescence pattern is illustrated in Figure 2, applying PS 26, while Ctrl 5 was used as negative control.

**ELISA screening of anti-CENP-F-positive sera**

The reactivity of pools of anti-CENP-F-positive sera and pools of control sera to overlapping 20-mer peptides covering the CENP-F amino acid sequence 1855-2189 was analyzed by ELISA. Figure 3 illustrates the reactivity of PS pool 1 (represented by PS 1, PS 2.1, PS 9.2, PS 11, PS 15, PS 17.2, PS 18, PS 26), Ctrl pool 1 (represented by Ctrl 1-8) and ANA pos pool 4 (containing eight ANA-positive sera) to the 33 CENP-F peptides, while Additional file 1: Figure S1 illustrates the reactivity of all the pools screened. As seen, CENP-F antibody reactivity was found to multiple peptides. Antibody reactivity of PS pools was found to be focused around three regions A4-A6, A12-A16 and A21-A23. No distinct reactivity was found to these regions when analyzing reactivity of control pools (healthy donor pool and Ctrl pools), although all of the healthy donor pools showed weak reactivity to peptide A6. Similarly, three out of five ANA positive pools showed weak reactivity to peptides A9 and A17. Moreover, the region A22-A24 was found to be recognized by these pools as well. However, as these sera were CENP-F negative, these patterns are believed to be related to other nuclear proteins.

Based on the collective findings, the peptides: A1, A4, A6, A9, A12-A16, A18, A21-A23, A27 and A29 were chosen for further analysis (marked with # in Figure 3). All of the available 42 samples from the 28 anti-CENP-F-positive patients and 86 Ctrl sera (56 from ANA screening (Figure 4), 20 from ELISA testing and 10 from healthy controls) were then tested individually for reactivity to the selected CENP-F peptides by ELISA. As seen in Figure 4, antibody reactivity was found to be concentrated around peptides A6, A13, A15 and A22, recognized by 23, 9, 7 and 7 anti-CENPF-positive patient sera, respectively. Of the 44 sera from 28 patients showing the NSp-II IIF pattern 7 did not react with any of the peptides. Three of these (PS3-5 were from patients, where only one sample was available, three (PS2.2-2.4) were from a patient, where only the first of four consecutive sera reacted in ELISA, and one (PS17.1) was the first of 3 consecutive sera, where the second (PS17.2) and third (PS17.3) showed reactivity with one and two peptides, respectively. The Ctrl sera (ANA-negative samples (n=30), ANA-positive samples (centromere (n=6), homogenous (n=10) and speckled (n=10) patterns) (Figure 4), CCP antibody-positive sera (n=10), DNA antibody-positive sera (n=10), healthy blood donors (n=10) only occasionally showed weak reactivity to the CENP-F peptides (Figure 4 and results not shown). Most importantly, the sera showing the typical centromere pattern, which resembles the NSp-II pattern, were negative in ELISA.

**Correlation between diagnosis and antibody profile**

In order to look for patterns of variation in the data set and in order to determine whether a correlation could be established between the CENP-F antibody reactivities and individual patient diagnoses, both a multivariate and a univariate analysis was used to evaluate the P-values of the contrasts between the diagnostic groups. For this, three scenarios were set: 1) all groups were regarded as different from each other; 2) the no neoplasia and the benign tumor groups were regarded as one; and 3) the benign tumor and the invasive cancer groups were regarded as one.

**Multivariate analysis of the fused matrix**

A principal component analysis (PCA), which describes the variation in the data set, was performed on the fused matrix and the scores of the resulting 15 PCs were analyzed in a spreadsheet in which the P-values for the contrasts between the diagnostic groups were calculated for each PC. Table 2 shows the P-values for the first six PCs. Out of all PCs only PC#1, PC#2, and PC#6 were found to describe statistically significant variations. The single significant contrast between the control and the benign tumor group in PC#4 was found to be the result of a single outlier and was therefore not taken into consideration. Figures 5A-D illustrate 2-dimensional projections of these three PCs and their respective loading plots. The diagnostic groups are represented by colors and can more or less be distinguished spatially from each other. Looking at the score plot in Figure 5A, the group with invasive cancer dominates the negative end of PC#1, while the control group forms a tilted ellipse around the center, intersected by a more vertical clustering of the no neoplasia group. The benign tumor group...
Table 1 Medical history and cancer cases of patients positive for NSp-II antibodies

| Group/ sample ID | NSp-II signal in IIF | Time delay in months | Registered cancer cases Topography/histology | Additional medical history |
|------------------|----------------------|----------------------|---------------------------------------------|---------------------------|
| Invasive cancer   |                      |                      |                                             |                           |
| PS 1             | Strong               |                      | Lung, small cell carcinoma                  |                           |
| PS 2.1           | Strong               | 0                    | Cervix uteri, carcinoma in situ             | Systemic lupus erythematosus |
| PS 2.2           | Medium               | 26                   |                                             |                           |
| PS 2.3           | Medium               | 74                   |                                             |                           |
| PS 2.4           | Medium               | 97                   |                                             |                           |
| PS 4             | Medium               |                      | Breast, Infiltrating duct carcinoma         |                           |
| PS 6.1           | Medium               | 0                    | Lung small cell carcinoma                   | Arthritis urica/Muscular rheumatism |
| PS 6.2           | Strong               | 1                    |                                             |                           |
| PS 8.1           | Medium               | 0                    | Lung, adenocarcinoma                        | Eye, benign tumor         |
| PS 8.2           | Medium               | 1                    |                                             |                           |
| PS 8.3           | Medium               | 4                    |                                             |                           |
| PS 9.1           | Medium               | 0                    | Ovary, clear cell adenocarcinoma            | Peritoneum and lymph node metastasis |
| PS 9.2           | Medium               | 1                    |                                             |                           |
| PS 9.3           | Medium               | 10                   |                                             |                           |
| PS 9.4           | Medium               | 18                   |                                             |                           |
| PS 12.1          | Strong               | 0                    | Brain, unspecified tumor                    | Sjögren’s syndrome/reumatoid arthritis |
| PS 12.2          | Medium               | 25                   |                                             |                           |
| PS 12.3          | Strong               | 51                   |                                             |                           |
| PS 12.4          | Medium               | 53                   |                                             |                           |
| PS 13            | Medium               |                      | Base of tongue, squamous cell carcinoma     | Carrier of Human T-lymphotrophic virus-1/Reactive arthritis |
| PS 15            | Strong               |                      | Esophagus, Squamous cell carcinoma          | Rheumatoid arthritis      |
| PS 16            | Medium               |                      | Breast, infiltrating duct carcinoma         | Bone or bone marrow, metastasis / Lymph node malignant tumor |
| PS 17.1          | Medium               | 0                    | Breast, infiltrating duct carcinoma         | Septicaemia               |
| PS 17.2          | Strong               | 14                   |                                             |                           |
| PS 17.3          | Medium               | 59                   |                                             |                           |
| PS 18            | Medium               |                      | Unknown site, adenocarcinoma                | Lung, malignant tumor     |
| PS 23            | Strong               |                      | Base of tongue, squamous cell carcinoma     | Oropharynx, malignant tumor |
| PS 27            | Strong               |                      | Lymph node, diffuse large cell lymphoma     |                           |
| Benign tumor      |                      |                      |                                             |                           |
| PS 3             | Weak                 |                      |                                             | Liver transplantation/Face; benign tumor |
| PS 19            | Weak                 |                      |                                             | Skin, benign tumor/Sjögren’s syndrome |
| PS 21            | Medium               |                      |                                             | Breast, benign cystic tumor |
| PS 24            | Strong               |                      |                                             | Neoplasia-associated polyneuropathy |
| PS 25            | Weak                 |                      |                                             | Breast, benign tumor      |
| No neoplasia      |                      |                      |                                             |                           |
| PS 5             | Strong               |                      |                                             | Septicaemia               |
| PS 7             | Weak                 |                      |                                             |                           |
| PS 10            | Weak                 |                      |                                             |                           |
| PS 11            | Strong               |                      |                                             | Parkinson’s disease       |
| PS 14            | Medium               |                      |                                             |                           |
could be forming a cluster in the overlap zone of the other groups, but due to the limited number of samples in this group, a clear pattern cannot be established. Observed perpendicular to this in Figure 5B, the overall pattern is more diffuse except for the control group that has accumulated in the bottom right corner. Based on the results illustrated in Figure 5, the P-values displayed in Table 2 was calculated, from which the following statements are clear: PC#1 correlates significantly with the contrasts posed by the invasive cancer group, and to a lesser extent with the contrast between the control and the no neoplasia groups. PC#2 correlates exclusively and significantly with the contrasts posed by the control group, although only weakly when the tumor group is involved, and PC#6 correlates even stronger with the contrasts posed by the control group. The benign tumor group is not clearly distinguished from the other groups, partly because it is only represented by five samples, and partly because it assumes a very intermediate profile.

Knowing what is described by the different PCs, the next step is to understand how the PCs themselves are described. To do this, the loading plots in Figure 5C and D were examined. The loading plots illustrate the projections of the 15 peptides onto the PCs in such a way that the greater the distance from zero a given peptide is placed along a PC, the greater “gravity” it imposes on the samples in the score plot. Therefore, the peptides in the negative end, of e.g. PC#1, are potentially responsible for pulling the samples towards this end, and since the negative end of PC#1 is dominated by invasive cancer samples, antibodies to these peptides are potentially correlated with invasive cancer. However, this cannot be unequivocally determined by an isolated view on the PCA, as a projection of a peptide can also pose a repulsive effect and thus inhabit a peripheral position in this capacity. To clarify this, the data obtained from the univariate analysis was considered.

### Univariate analysis of the fused matrix

P-values of the contrasts between the groups were calculated for each of the 15 peptides in the fused matrix using the Student’s t-test. The results are shown in Table 3. Beginning in the negative end of PC#1, antibodies to peptide A27 have the most negative loading score. At a first glance, it seems as if these antibodies pose a strong traction upon the invasive cancer group, but according to Table 2 they actually pose a strong repulsive action upon the no neoplasia group, while they do not distinguish between the other groups. In terms of antibody profile this means that the no neoplasia group has a significantly lower expression of antibodies against peptide A27 than the other groups. CENP-F antibodies to peptides A12 and A14 appear to have the same level of impact on PC#1. Their univariate profiles, however, are very different. Antibodies to peptide A12 do not specify much contrast, antibodies to peptide A14 pose a more hierarchical pattern, being most prevalent in the invasive cancer group, less so in the benign tumor and control groups and least in the no neoplasia group. The benign tumor group was not distinguished by antibodies to peptide A14. Closer to zero of PC#1 were CENP-F antibodies to peptide A9. According to Table 3 these

---

**Table 1 Medical history and cancer cases of patients positive for NSp-II antibodies** (Continued)

| PS 20 | Medium |
| PS 22 | Weak |
| PS 26 | Strong |
| PS 28 | Medium |

---

**Figure 2 Immunofluorescence on HEp-2 cells with anti-CENP-F-positive serum and control serum.** (A) Reactivity of anti-CENP-F-positive patient serum (PS 26). Cells at different stages in the cell cycle are marked. G1-S: G1-S phase; G2: G2 phase; P: prophase; M: metaphase; A: anaphase; T: telophase. (B) Reactivity of CENP-F-negative patient serum (Ctrl 5).
antibodies are highly specific for the invasive cancer group, for which the expression was significantly elevated compared to the control and no neoplasia groups. Antibodies to peptide A16 were also more frequent in the invasive cancer group when compared to the no neoplasia group, but not when compared to the control group.

Looking at PC#2 and PC#6, especially antibodies to peptides A6 and A13 were placed in the periphery. According to the univariate data analysis, antibodies to peptide A6 were interesting, as they posed significant contrasts for all pairs of groups in which the control group was included, meaning that the expression of antibodies to A6 was significantly raised in all anti-CENP-F-positive sera compared to the controls.

Multivariate analysis of the complete matrix
A PCA of the complete matrix was performed to investigate the change in antibody profile as a function of the time of blood sampling. This was performed by analyzing the six patients that were represented by more than one blood sample (PS 2, PS 6, PS 8, PS 9, PS 12 and PS 17). Additional file 2: Figure S2 illustrates the 2D score plots of PC#1 and PC#2 for each of the six patients and reveals a general pattern of migration towards the negative end of PC#1 as a function of blood sampling time, suggesting a correlation between diagnosis/tumor stage and sample time.

Discussion
In this study, we analyzed the correlation between diagnoses and the presence of antibodies to CENP-F, determined by IIF using HEp-2 cells. We confirmed that 50% of anti-CENP-F-positive individuals had a cancer diagnosis, as reported by others [9-11,25,26]. The remaining 50% mainly had a benign tumor or a connective tissue disease.

Moreover, we analyzed the presence of CENP-F antibodies directed to the predicted SMC A domain using overlapping 20-mer peptides. In this regard, it must be emphasized that we most likely do not detect antibodies to conformational and discontinuous epitopes and that we only used peptides from the SMC A domain. This is a major difference compared to earlier studies using fragments of CENP-F. Moreover, the study material was small, which is a limitation to the conclusions drawn here. Despite these limitations, the results were significant and may have important implications for future studies.

The ELISA results revealed that CENP-F antibody expression to eight of the 15 screened peptides (A1, A6, A9, A13, A14, A18, A21 and A23) was increased significantly in the invasive cancer compared to the control group. Moreover, CENP-F antibody expression to five peptides (A9, A14, A16, A27 and A29) was increased significantly in the invasive cancer group compared to the no neoplasia group. Especially the expression of CENP-F antibodies to peptides A9 and A14 was elevated in the invasive cancer group exclusively. CENP-F antibody reactivity to other peptides, such as A18, A21 and A23, also correlated with invasive cancer diagnoses, but not in an exclusive manner. CENP-F antibody expression to peptide A6 exhibited a strong correlation with all of the anti-CENP-F-positive groups (invasive cancer,
Figure 4 Heat map of antibody profiles showing reactivity to selected peptides in individual patient serum samples. Normalized reactivity is illustrated in grey scales. ANA positive samples 1-10 had a homogenous nuclear staining, 11-20 had a speckled nuclear staining and 21-26 had a centromere pattern.
benign tumor and no neoplasia) compared to the controls. Similarly, CENP-F antibody expression to peptide A27 was increased in all groups except from the no neoplasia group, a characteristic that was partly shared by peptide A14 and A16 as well. The peptides A4 and A15 did not represent any contrast at all, but have still been included in the analysis, as they did display reactivity during the preliminary pool screenings. This indicated that their antibody specificity was not correlated with any of the groups. For peptide A15, an epitope has been finely mapped in a parallel study in which two monoclonal antibodies recognized this peptide out of the 33 peptides (A1-A33) [24].

More generally, as seen in Table 3, it could be interpreted that the CENP-F antibody expression profile was generally increased in the invasive cancer group.

Table 2 PCA of the fused matrix

|                                | PC#1 (27.94%) | PC#2 (11.46%) | PC#3 (9.29%) | PC#4 (7.85%) | PC#5 (7.53%) | PC#6 (7.02%) |
|--------------------------------|---------------|---------------|--------------|--------------|--------------|--------------|
| Control vs no neoplasia        | 0.0139 *      | 0.0006 **     | 0.1211       | 0.3422       | 0.0564       | 0.0001 ***   |
| Control vs benign tumor        | 0.6695        | 0.0196 *      | 0.0704       | 0.0093 **    | 0.0818       | 0.0146       |
| Control vs invasive cancer     | 0.0014 **     | 0.0052 **     | 0.1441       | 0.7088       | 0.1934       | 0.0006 ***   |
| No neoplasia vs benign tumor   | 0.0114 *      | 0.6004        | 0.0843       | 0.4140       | 0.5076       | 0.5799       |
| No neoplasia vs invasive cancer| 0.0005 ***    | 0.9463        | 0.9431       | 0.4794       | 0.5665       | 0.4471       |
| Benign tumor vs invasive cancer| 0.0509        | 0.7425        | 0.1099       | 0.1423       | 0.6938       | 0.9850       |
| Control vs no neoplasia/benign tumor | 0.00001 *** | 0.8995        | 0.4505       | 0.7200       | 0.8283       | 0.5950       |
| Control vs invasive cancer     | 0.0126 *      | 0.0032 **     | 0.5683       | 0.1909       | 0.2926       | 0.0003 ***   |
| No neoplasia vs benign tumor/invasive cancer | 0.0018 * | 0.8412        | 0.5285       | 0.2759       | 0.4735       | 0.4262       |

P-values for the contrasts between the four groups (Control, no neoplasia, benign tumor and invasive cancer) were calculated for each PC#1-#6 based on PCA of the fused matrix. *: P<0.05, **: P<0.01, ***: P<0.001.

Figure 5 Multivariate analysis of the fused matrix. (A): Score plot of PC#1 and PC#2. (B): Score plot of PC#2 and PC#6. (C): Loading plot of PC#1 and PC#2. (D): Loading plot of PC#2 and PC#6. Percentage of complete variation of data described by the individual PCs is stated in parenthesis. Patient groups are illustrated as follows: brown: control, dark blue: no neoplasia, yellow: benign tumor, light blue: invasive cancer.

Welner et al. Molecular Cancer 2013, 12:95 http://www.molecular-cancer.com/content/12/1/95
Autoimmune illnesses have been reported. Mahler et al. described to express autoantibodies against CENP-E, other patients with systemic sclerosis have been described to express autoantibodies against CENP-A and CENP-B. Developing an antibody response against histone H3 that the autoimmune response is indeed antigen-driven [47] and ANAs have previously been described in several types of cancer including ovarian and lung cancer [48-51].

In conclusion, we have developed an ELISA system for detecting CENP-F autoantibodies and we confirm the conclusion reached by Fritzler et al., that although such antibodies have a low sensitivity, the positive predictive value for cancer in clinical samples submitted for ANA analyses is approximately 50% and the positive predictive value for neoplasia even higher. In future studies, we would like to extend these studies to the whole CENPF sequence using longer peptides and to larger patient cohorts.

Methods
Peptide fragments for analysis
The human CENP-F sequence (Uniprot KB ID: P49454), comprising 3210 amino acids, was used to construct 33 overlapping peptides, A1-A33, which span the amino acid sequence 1855-2189 (Figure 1). The length of each peptide was 20 amino acids, with an overlap of 10 amino acids to the next peptide. At the N-terminus, a cysteine residue was added in order to have the possibility to screen the peptides using CovaLink™ technology (see peptide ELISA). The peptides A1-A16, A18, A20-A33 were purchased from Schäfer-N (Copenhagen, Denmark), while peptides A17 and A19 were synthesized as described elsewhere [24]. The peptides, A1-A33, are listed in the supplementary table (Additional file 3: Table S1).

Serum samples
Sera were routinely screened for the presence of antinuclear antibodies (ANA) by IIF using HEp-2 cells as

Table 3 Univariate analysis of the fused matrix

|                  | A1    | A4    | A6    | A9    | A12   | A13   | A14   | A15   | A16   | A18   | A21   | A22   | A23   | A27   | A29   |
|------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Control vs no neoplasia | 0.60  | 0.08  | 0.00***| 0.06  | 0.32  | 0.81  | 0.00**| 0.87  | 0.00***| 0.23  | 0.77  | 0.07  | 0.60  | 0.00**| 0.00***|
| Control vs benign tumor | 0.84  | 0.99  | 0.00***| 0.30  | 0.12  | 0.36  | 0.06  | 0.09  | 0.51  | 0.32  | 0.28  | 0.1   | 0.55  | 0.09  | 0.18  |
| Control vs invasive cancer | 0.04* | 0.63  | 0.00***| 0.00***| 0.05  | 0.05* | 0.01* | 0.18  | 0.49  | 0.00**| 0.00**| 0.29  | 0.01**| 0.44  | 0.92  |
| No neoplasia vs benign tumor | 0.88  | 0.36  | 0.76  | 0.19  | 0.68  | 0.61  | 0.29  | 0.27  | 0.19  | 0.29  | 0.57  | 0.05* | 0.91  | 0.03* | 0.13  |
| No neoplasia vs invasive cancer | 0.16  | 0.23  | 0.83  | 0.01**| 0.08  | 0.27  | 0.01**| 0.34  | 0.02* | 0.56  | 0.11  | 0.07  | 0.06  | 0.00**| 0.01* |
| Benign tumor vs invasive cancer | 0.26  | 0.83  | 0.55  | 0.35  | 0.05* | 0.72  | 0.07  | 0.06  | 0.53  | 0.00**| 0.42  | 0.60  | 0.11  | 0.09  | 0.36  |
| Control vs no neoplasia/benign tumor | 0.62  | 0.21  | 0.00***| 0.55  | 0.13  | 0.82  | 0.00***| 0.34  | 0.01**| 0.58  | 0.84  | 0.70  | 0.48  | 0.00***| 0.47  |
| No neoplasia vs invasive cancer | 0.11  | 0.31  | 0.66  | 0.02* | 0.02* | 0.32  | 0.00**| 0.09  | 0.04  | 0.16  | 0.13  | 0.33  | 0.02* | 0.00**| 0.65  |
| Control vs benign tumor/invasive cancer | 0.11  | 0.69  | 0.00***| 0.00**| 0.30  | 0.06  | 0.11  | 0.63  | 0.77  | 0.05* | 0.00**| 0.15  | 0.04* | 1.00  | 0.56  |
| No neoplasia vs benign tumor/invasive cancer | 0.23  | 0.22  | 0.97  | 0.02* | 0.20  | 0.28  | 0.03* | 0.67  | 0.03* | 0.99  | 0.12  | 0.04* | 0.14  | 0.1*  | 0.07  |

P-values of the contrasts between the groups were calculated for each of the 15 peptides in the fused matrix. Italics correlate negatively.
*: P<0.05, **: P<0.01, ***: P<0.001.
described below. Out of approximately 175,000 samples, submitted for routine ANA screening over a period of approximately 8 years, 42 samples from 28 patients were positive for the N5p-II pattern, characteristic for CENP-F antibodies [25]. Most patients were represented by a single serum sample, while a few were represented by up to four samples (Table 1). Each individual anti-CENP-F-positive sample was given a unique identification code, PS, followed by a number from 1-28 referring to the patient. A decimal number from 1-4 was added to the samples from patients represented more than once, 1 referring to the oldest sample and 4 to the most recent sample. The following six patients were represented more than once: PS 2 (PS 2.1-2.4), PS 6 (PS 6.1-6.2), PS 8 (PS 8.1-8.3), PS 9 (PS 9.1-9.4), PS 12 (PS 12.1-12.4) and PS 17 (PS 17.1-17.3). In addition, 30 samples that all tested negative for ANA were used as controls. These are referred to as Ctrl 1-30. A list of the medical histories and registered cancer diagnoses among patients positive of CENP-F antibodies was acquired retrospectively from the National Board of Health (Table 1). Based on this, analyzed samples were grouped as follows: Controls (30/58), patients without neoplasia (9/58), patients with benign tumors (5/58), patients with invasive cancer (14/58). In addition 10 sera positive for CCP antibodies, 10 sera positive for DNA antibodies and 10 sera from healthy blood donors were analysed by ELISA. All serum samples were acquired from the serum bank at Statens Serum Institut. **Pretreatment of serum for inactivation of the complement system**

Non-specific binding in serum screening experiments is a well-known cause of measurement uncertainty and false positive results. Aluminum hydroxide pre-treatment has been found to reduce non-specific binding in ELISA (Güven et al., unpublished data). Pretreatment of sera was performed by mixing 1:1 with aluminum hydroxide (Alhydrogel 2%, Brenntag Biosector, Frederikssund, Denmark). After having incubated on a shaker for 1 h at room temperature (RT) the sample was centrifuged, the supernatant diluted 1:100 in Tris-Tween-NaCl (TTN) buffer (0.05 M Tris, 1% Tween 20, 0.3 M NaCl, pH 7.5) and applied for ELISA.

**Indirect immunofluorescence for anti-nuclear antibodies**

Sera were diluted in phosphate-buffered saline (PBS) (10 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub>, 0.15 M NaCl, pH 7.2) (1:160) and 20 μl were applied to wells of glass slides with fixed HeP-2 cells (Immunoconcepts, Sacramento, CA, USA) and incubated at RT in a humidified chamber. Wells were rinsed with PBS, and 20 μl FITC-conjugated rabbit IgG against human IgG (DAKO, Copenhagen, Denmark), diluted in PBS (1:40), were applied to the wells and incubated 30 min. The wells were rinsed with PBS and the slides were mounted with coverslips and inspected with a fluorescence microscope (Aristoplan (Leica), BH2 (Olympus) or Eurostar (Euroimmun)). The immunofluorescence pattern and the intensity were graded by intensity of 0 (negative), +1 (weak), +2 (medium), 3+ (strong) and recorded essentially as described elsewhere [52].

**Peptide enzyme-linked immunosorbent assay (ELISA)**

In initial experiments, Covalink plate immobilization was compared with Maxisorp plate adsorption. The covalink plates showed too high background and further experiments were done with simple adsorption in Maxisorp plates. The wells of a 96-well Maxisorp microtitre plate (Nunc, Roskilde, Denmark) were coated with 1.5 μg/well peptide dissolved in carbonate buffer (15 mM Na<sub>2</sub>CO<sub>3</sub>, 35 mM NaHCO<sub>3</sub>, 0.001% phenol-red, pH 9.6) and incubated over night at 4°C. Wells were rinsed with TTN buffer and incubated with sera (with or without aluminum hydroxide pretreatment) diluted in TTN (1:200) for 1 h. The wells were rinsed with TTN (3 x 5 min) and incubated 1 h with alkaline phosphatase-conjugated goat IgG against human IgG (Sigma Aldrich, Steinheim, Germany) followed by three washes with TTN buffer (5 min each). Bound antibodies were quantified using para-nitrophenylphosphate (1 mg/mL) (Sigma Aldrich) dissolved in alkaline phosphatase substrate buffer (1 M diethanolamine, 0.5 mM MgCl<sub>2</sub>, pH 9.8). After sufficient color reaction, the absorbance was measured at 405 nm on a Thermomax microtitre plate reader (Molecular Devices, Menlo Park, CA, USA). All samples were analyzed in duplicate.

**ELISA for CCP and DNA antibodies**

CCP antibodies were determined with the CCP2 ELISA kit (Eurodiagnostica, Malmö, Sweden) and DNA antibodies were determined by ELISA with the VarElisa kit (Thermo Scientific, Uppsala, Sweden) following the instructions of the manufacturers.

**Normalization of data**

All sera-pool screenings were normalized relative to internal reference sera and to each other.

**Multivariate data analysis**

Multivariate data analysis was performed using the principal component analysis (PCA) software, LatentiX (Latent5, downloaded from latentix.com). Prior to this, the normalized data for the individual screenings was mounted in two different data matrices. One matrix, referred to as the complete matrix, contained data from all the individual screenings, while the other, referred to as the fused matrix, contained the data from the patients represented by multiple samples fused into one average
data unit per patient. This was done to allow equal impact of each patient. Both matrices were transformed logarithmically prior to analysis in order to approximate a Gaussian distribution. In LatentiX, the data was transformed using the autoscale function and the PCA models were calculated without validation.

**Additional files**

**Additional file 1: Figure S1.** Heat map of antibody profiles showing reactivity of sera pools to peptides 1-33. Sera pools PS pool 1, PS pool 2, individual anti-CENP-F-positive pools PS 12, PS 24 and PS 27 (19 in total), Ctrl pool 1, ANA negative pools 1-5, healthy donor pools 1-4 and ANA positive pools 1-5 were analyzed for reactivity. Normalized reactivity is illustrated in grey scales.

**Additional file 2: Figure S2.** Multivariate analysis of the complete matrix. Percentage of complete variation of data described by the individual PCs is stated in parenthesis. Consecutive blood samples for patients with multiple samples are highlighted in yellow. A: PS 17, B: PS 12, C: PS 9, D: PS 8, E: PS 2, F: EG 3. Patient groups are illustrated as follows: brown: control, dark blue: no neoplasia, yellow: benign tumor, light blue: invasive cancer.

**Additional file 3: Table S1.** Overlapping CENP-F peptides applied for screening.

**Abbreviations**

ANNA: Antinuclear antibodies; CENP-F: Centromere protein-F; ELISA: Enzyme-linked immunosorbent assay; IIF: Indirect immunofluorescence; NHL: Non-Hodgkin’s lymphoma; NSp-II: Nuclear speckled pattern-II; PBS: Phosphate-buffered saline; PC: Principal component; PCA: Principal component analysis; RIA: Radioimmunoassay; RT: Room temperature; SMC: Structural maintenance of chromosomes; TTN: Tri-Tween-NaCl.

**Competing interests**

The authors declare no competing interests.

**Authors’ contributions**

SW conducted experiments as well as carried out data analysis and manuscript writing. NHT conducted preliminary experiments, peptide synthesis, participated in intellectual discussion of the data and manuscript writing. PRH and GH conducted design study, participated in intellectual discussion, and manuscript writing. NHT conducted preliminary experiments, peptide synthesis, participated in intellectual discussion of the data and manuscript writing. WH: Characterization of a novel 350-kilodalton nuclear phosphoprotein that is specifically involved in mitotic-phase progression. J Mol Cell Biol 1995, 20:307–329.

**Acknowledgements**

We wish to thank Ewa Kogutowska and Bettina Eide Holm for technical assistance and the serum bank at Statens Serum Institut for providing CENP-F sera and retrieved medical patient histories. All authors read and approved the final manuscript.

**References**

1. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L: The case for early detection. Nat Rev Cancer 2003, 3:243–252.
2. Duffy MJ: Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract 2013, 22:4–11.
3. Mo MH, Chen L, Fu Y, Wang W, Fu SW: Cell-free circulating miRNA biomarkers in cancer. J Cancer 2012, 3:432–448.
4. NogueiradaCosta A, Hercseg Z: Detection of cancer-specific epigenomic changes in biofluids: powerful tools in biomarker discovery and application. Mol Oncol 2012, 6:704–715.
5. Balic M, Williams A, Lin H, Datar R, Cote RJ: Circulating tumor cells: from bench to bedside. Annu Rev Med 2013, 64:31–44.
6. Desmetz C, Mange A, Maudelonne T, Solasol J: Autoantibody signatures: progress and perspectives for early cancer detection. J Cell Mol Med 2011, 15:2033–2042.
7. Tosthofer TB, Rubin M: Paraneoplastic neurological syndromes: a review. Neurologist 2009, 15:23–31.
8. Graus F, Dalmau J: Paraneoplastic neurological syndromes. Curr Opin Neurol 2012, 25:795–801.
9. Casiano CA, Humbel RL, Peebles C, Covini G, Tan EM: Autoimmunity to the cell cycle-dependent centromere protein p330/CENP-F in disorders associated with cell proliferation. J Autoimmun 1995, 8:375–386.
10. Rattner JB, Rees J, Whitehead CM, Casiano CA, Tan EM, Humbel RL, Conrad K, Fritzler MJ: High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med 1997, 20:288–319.
11. Benjimon C, Salles G, Moreira A, Guymard S, Coffier B, Bienvenu J, Fabien N: Prevalence of anticientromere F protein autoantibodies in 347 patients with non-Hodgkin’s lymphoma. Ann N Y Acad Sci 2005, 1050:319–326.
12. Muro Y, Kaminoto T, Hagio M: Anti-mitosis antibodies in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplantation 1997, 19:961–963.
13. Zhu X, Mandzi MA, Chang KH, Liu CY, Chen CF, Shan B, Jones D, Yang-Feng TL, Lee WH: Characterization of a novel 300-kilodalton nuclear phosphoprotein that is specifically involved in mitotic-phase progression. J Mol Cell Biol 1995, 20:307–329.
14. Ma L, Zhao X, Zhu X: Mitosin/CENP-F in mitosis, transcriptional control, and differentiation. J Biomed Sci 2006, 13:202–213.
15. Varis A, Salmena AL, Kallio Mi. CENP-F (mitosin) is more than a mitotic marker. Chromosoma 2006, 115:288–295.
16. Zhu X, Ding L, Pei G: Carboxyl terminus of mitosin is sufficient to confer spindle pole localization. J Cell Biochem 1997, 66:441–449.
17. The national center for biotechnology information database. http://www.uniprot.org/uniprot/P49464.
18. Liao H, Winkfen R, Mack G, Rattner JB, Yen TJ: CENP-F is a protein of the nuclear matrix that assembles into kinetochores at late G2 and is rapidly degraded after mitosis. J Cell Biol 1995, 130:507–518.
19. Zhu X: Structural requirements and dynamics of mitosin-kinetochore interaction in M phase. Mol Biol Cell 1999, 19:1016–1024.
20. Zhu X, Wang P, Fan L, Li Y, Ma L, Yang Z, Yu W, Jing N, Zhu X: Mitosin/ CENP-F as a negative regulator of activating transcription factor-4. J Biol Chem 2005, 280:13973–13977.
21. Zhu X, Chang KH, He D, Mancini MA, Brinkley WR, Lee WH: The C terminus of mitosin is essential for its nuclear localization, centromere/kinetochore targeting, and dimerization. J Biol Chem 1995, 270:19545–19550.
22. Choudhary C, Kumar C, Grad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834–840.
23. Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P: Farnesyl transferase inhibitors block the farnesylation of CENP-F and CENP-E and alter the association of CENP-E with the microtubules. J Biol Chem 2000, 275:30451–30457.
24. Welner SA, Trier NH, Houen G, Hansen PR: Identification and mapping of a linear epitope of centromere protein F using monoclonal antibodies. J Pediatr 2013, 199:96–101.
25. Fritzler MJ, Rattner JB, Luft LM, Edworthy SM, Casiano CA, Peebles C, Mahler M: Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev 2011, 10:194–200.
26. Fritter MJ: The clinical paradox of esoteric and novel autoantibodies. Autoantigens, autoantibodies. Autoimmun 2009, 6:71–88.
27. Mahler M, Mierau R, Genth E, Blumberg M: Development of a CENP-a/CENP-B-specific immune response in a patient with systemic sclerosis. Arthritis Rheum 2002, 46:1866–1872.
28. Hambouch K, Rodríguez C, Pérez-Venegas J, Rodríguez I, Astola A, Ortiz M, Yen TJ, Bennani M, Valdiya MW: Anti-CENP-F autoantibodies in
scleroderma patients with features of autoimmune liver diseases. Clin Chim Acta 2011, 412:2267–2271.
29. Rattner JB, Rees J, Arnett FC, Reveille JD, Goldstein R, Fritzler MJ. The centromere kinesin-like protein, CENP-E. An autoantigen in systemic sclerosis. Arthritis Rheum 1996, 39:1355–1361.
30. Saito A, Muray Sugiura K, Iino M, Yoda K, Tomita Y. CENP-O, a protein localized at the centromere throughout the cell cycle, is a novel target antigen in systemic sclerosis. J Rheumatol 2009, 36:781–786.
31. Hsu TC, Chang CH, Lin MC, Liu ST, Yen TJ, Tsai GJ. Anti-CENP-H antibodies in patients with Sjögren’s syndrome. Rheumatol Int 2006, 26:298–303.
32. Ford AL, Kurien BT, Harley JB, Scofield RH. Anti-centromere autoantibody in a patient evolving from a lupus/Sjögren’s overlap to the CREST variant of scleroderma. J Rheumatol 1998, 25:1419–1424.
33. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57–70.
34. Yang ZY, Guo J, Li N, Qian M, Wang SN, Zhu XL. Mitotic/CENP-F is a conserved kinetochore protein subjected to cytoplasmic dynein-mediated poleward transport. Cell Res 2003, 13:275–283.
35. Feng J, Huang H, Yen TJ. CENP-F is a novel microtubule-binding protein that is essential for kinetochore attachments and affects the duration of the mitotic checkpoint delay. Chromosoma 2006, 115:320–329.
36. Bomont P, Maddox P, Shah JV, Désai AB, Cleveland DW. Unstable microtubule capture at kinetochores depleted of the centromere-associated protein CENP-F. EMBO J 2005, 24:3927–3939.
37. Holt SV, Vergnolle MA, Hussein D, Wozniak MJ, Allan VJ, Taylor SS. Silencing cenp-f weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint. J Cell Sci 2005, 118:4889–4900.
38. Yang Z, Guo J, Chen Q, Ding C, Du L, Zhu X. Silencing mitosin induces misaligned chromosomes, premature chromosome decondensation before anaphase onset, and mitotic cell death. Mol Cell Biol 2005, 25:4062–4074.
39. Báez A, Torres K, Tan EM, Pommier Y, Casiano CA. Expression of proliferation-associated nuclear autoantigens, p330d/CENP-F and PCNA, in differentiation and in drug-induced growth inhibition using two-parameter flow cytometry. Cell Prolif 1996, 29:183–96.
40. Cao JY, Liu L, Chen SP, Zhang X, Mi YJ, Liu ZG, Li MZ, Zhang H, Qian CN, Shao JY, Fu LW, Xia YF, Zeng MS. Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma. Mol Carcinog 2010, 9:237.
41. Ueda S, Kondoh N, Tsuda H, Yamamoto S, Asakawa H, Fukatsu K, Kobayashi T, Yamamoto J, Tamura K, Ishida J, Abe Y, Yamamoto M, Mochizuki H. Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer. BMC Cancer 2008, 8:384.
42. Landberg G, Erlanson M, Roos G, Tan EM, Casiano CA. Nuclear autoantigen p330d/CENP-F: a marker for cell proliferation in human malignancies. Cytometry 1996, 25:90–98.
43. Erlanson M, Casiano CA, Tan EM, Lindh J, Roos G, Landberg G. Immunohistochemical analysis of the proliferation associated nuclear antigen CENP-F in non-Hodgkin’s lymphoma. Mod Pathol 1999, 12:69–74.
44. de la Guardia C, Casiano CA, Trinidad-Pinedo J, Báez A. CENP-F gene amplification and overexpression in head and neck squamous cell carcinomas. Head Neck 2001, 23:104–112.
45. Esquerra RI, Iia L, Kaneko T, Sakamoto K, Okada N, Takagi M. Immunohistochemical analysis of centromere protein F expression in buccal and gingival squamous cell carcinoma. Pathol Int 2004, 54:82–89.
46. Shigemitsu H, Mizuta K, Higashiaiwa K, Yoneda S, Ono S, Kamata N. Correlation of CENP-F gene expression with tumor-proliferating activity in human salivary gland tumors. Oral Oncol 2005, 41:716–722.
47. Tan EM, Muro Y, Pollard KM. Autoantibody-defined epitopes on nuclear antigens are conserved, conformation-dependent and active site regions. Clin Exp Rheumatol 1994, 12(Suppl 11):27–31.
48. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001, 60:133–41.
49. Racchelli V, Prete M, Minosa C, Favaio E, Penosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 2008, 7:352–358.
50. Bei R, Maxuelli L, Palumbo C, Modesti M, Modesti A. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: inflammation in their induction and impact on tumor growth. Cancer Lett 2009, 281:8–23.
51. Heegaard NH, West-Narager M, Tanassi JT, Houen G, Nedergaard L, Høgdall C, Høgdall E. Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival. PloS One 2012, 7(3):e39997.
52. Wik AS, Høier-Madsen M, Forslid J, Charles P, Neyrowitz J. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 2010, 35:275–290.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit